Generation of <i>ex vivo</i> autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy.

ABSTRACT: CD19CAR-T cell therapy demonstrated promising outcomes in relapsed/refractory B-cell malignancies. Nonetheless, the limited T-cell function and ineffective T-cell apheresis for therapeutic purposes are still concern in heavily pretreated patients. We investigated the feasibility of generating hematopoietic stem cell-derived T lymphocytes (HSC-T) for cancer immunotherapy. The patients' autologous peripheral blood HSCs were enriched for CD34⁺ and CD3⁺ cells. The CD34⁺ cells were then cultured following three steps of lymphoid progenitor differentiation, T-cell differentiation, and T-cell maturation processes. HSC-T cells were successfully generated with robust fold expansion of 3735 times. After lymphoid progenitor differentiation, CD5⁺ and CD7

SUBMITTER: Maneechai K 

PROVIDER: S-EPMC11467635 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature